AGE Reader

Key publications

The AGE Reader has been validated in over 200 peer-reviewed publications. Please find below a selection of key publications in several clinical areas:

CV Risk in the general population:

• Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. van Waateringe R et al. Diabetologia. 2019 Feb;62(2):269-280 Epub

CV Risk in Diabetes patients:

• Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus.  Lutgers H. et al, Diabetologia, 2009; 52(5): 789-797
• Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study. Noordzij M.J. et al. Diabet Med. 2012 Dec;29(12):1556-61.
• Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease. Gerrits E. et al. Diabetes Care. 2008; 31: 517-521
• Skin Autofluorescence – A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes. A. Stirban & L. Heinemann European Endocrinology, 2014;10(2):106–10. Full text available.

CV Risk in Atherosclerosis patients:

• Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease. de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2014 Feb 13.

CV Risk in Kidney disease patients:

• Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3. McIntyre N. et al. Clin J Am Soc Nephrol. 2011 Sep 1. Epub
• Skin-Autofluorescence Is an Independent Predictor of Graft Loss in Renal Transplant Recipients. Hartog J. et al. Transplantation, Volume 87, Number 7, April 15, 2009.

Technical validation:

• Simple non-invasive assessment of advanced glycation endproducts accumulation. Meerwaldt R et al, Diabetologia, 2004; 47:1324-1330